Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its ...

Spirit Airlines (SAVE) extends its debt refinancing deadline with the US Bank National Association, sending the stock soaring ...

A group of U.S. senators are digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...

Led by Sen. Dick Durbin of Illinois, senators question if direct-to-consumer website telehealth deals are a new way around ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

The latest update is out from Mangoceuticals, Inc. ( (MGRX) ).